Editorial Podcasts

The top five episodes of our podcast in the year 2024, highlighted.

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.

In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.

In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.

Gadi Saarony, CEO of Advarra discusses the current state of diversity in clinical trials and how industry needs to be more proactive in addressing it.

Micah Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses what ClinEco is and what attendees can expect at SCOPE.

Flo Mowlem, VP of Science at ObvioHealth discusses digital study design—touching on how to best manage data and medical devices.

Throughout 2023, guests of the Applied Clinical Trials podcast spoke on a number of topics including clinical research in rare disease areas, data, and artificial intelligence.

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

With so many new solutions and other technologies appearing in the clinical trials space, how are stakeholders choosing which ones are best for them and how are these advancements translating to the actual clinic?

While clinical research in rare diseases has many unique operational challenges, there is plenty of work being done to advance it and bring effective therapies to patients.

With the recent boom in artificial intelligence (AI), industry is finding ways to best utilize it in advancing the development of potential therapies.

New models such as IROs are changing the way industry views the current site landscape and addressing challenges.

Innovative pharma companies are stepping up to integrate digital health technology to advance pharmaceutical drug and medical device development, in both the healthcare and research worlds, to achieve better measurements and outcomes.

The evolution of data and digital health uses in both the healthcare and research worlds is bringing the two closer together for the good of patients.

Integrated research organizations (IROs) are creating a shift in the way clinical trials are operated, bringing new methods for enrollment and building patient-physician relationships.

From startups to major research organizations, early-phase research can be managed in different ways depending on the company.

The many sources of data source in clinical trials can be overwhelming, but the data itself can be used positively to guide clinical operations decision-making.

Jennifer Duff, General Manager, Zelta Clinical Trials Solutions, Merative (formerly IBM Watson Health), discusses her leadership philosophy, major technological changes are impacting clinical trials operations professionals today and in the future, plus much more.

Chris Learn, PhD, PMP, Vice President, Cell and Gene Therapy Center of Excellence, Parexel describes highlights of his career, what originally spurred his interest in clinical research, the current landscape of CGTs and much more.

Doug Warner, MD and CMO for eFFECTOR Therapeutics, discusses the complexities of oncology clinical trials, the important relationship medical directors should have with their clinical study teams, and more.

Peter Benton, President and CO-CEO for Worldwide Clinical Trials, speaks about his unconventional entrance into the industry, advice for clinops professionals, and much more.

Sindhu Ramchandren, MD, Director, Clinical Leader, Neuroscience at Janssen, discusses the importance of having physicians involved in clinical trials, walks us through her career path and more.

Gabriele Brambilla, CEO of Alira Health, discusses the ever-evolving landscape of real-world data.

Rose Blackburne, MD, MBA, Vice President, Global Head, General Medicine, PPD Clinical Research, Thermo Fisher and Margarita Nunez, MD, Principal Investigator, Synexus NY / Accelerated Enrollment Solutions New York discuss their panel at the recent Health Equity in Clinical Trials Congress in Boston last month; share insights into how diversity can be improved at the site and CRO; and the hope that clinical trial awareness and diversity can be discussed with all levels of stakeholders in healthcare to improve drug development worldwide.

Ira C. Spector, PhD, MBA, CEO and Co-Founder, SFA Therapeutics discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.

Beth MacEntee Pileggi, Head of Global Case and Safety Data Management with Janssen Pharmaceuticals of Johnson & Johnson, and Co-Lead of TransCelerate’s Pharmacovigilance Agreements Optimization Initiative, discusses the importance of safety, collaboration, TransCelerate’s positive role in the pharma industry and her passion for PV.